Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Antiautoimmune Drug Treatment Combined with Bone Marrow Transplant Cures Mouse Model of Type I Diabetes

By BiotechDaily International staff writers
Posted on 12 Jun 2013
Treatment with a drug to block autoimmune attack combined with transplantation of adult bone marrow cells or purified bone marrow progenitor cells restored the population of insulin-producing pancreatic beta cells and cured a mouse model of type I diabetes.

Investigators at the University of Missouri (Columbia, USA) had previously shown that a peptide drug (Ig-GAD2 ) comprising a 14 amino acid sequence isolated from the enzyme glutamic acid decarboxylase, induced immune modulation in hyperglycemic mice that was able to control pancreatic inflammation, stimulate beta-cell regeneration, and prevent type I diabetes progression. However, this treatment was unable to reverse the course of the disease despite eradication of inflammatory immune cells from the pancreas.

In a paper published in the May 28, 2013, online edition of the journal Diabetes the investigators reported that the reason for this failure was linked to damage done by autoimmune attack to the capillaries that supply blood to the pancreas. To repair this damage they injected diabetic rats with either bone marrow cells or purified bone marrow progenitor cells in combination with Ig-GAD2.

The investigators reported that when the mice received bone marrow cells together with Ig-GAD2, in addition to immune modulation there was concomitant formation of new beta- and endothelial cells in the pancreas. The new beta cells were of host origin while the donor bone marrow cells gave rise to the endothelial cells. On the other hand, transfer of purified bone marrow endothelial progenitors instead of whole bone marrow cells sustained both beta- and endothelial cell formation and reversal of diabetes.

Related Links:
University of Missouri




comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.